GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadrenal Therapeutics Inc (NAS:CVKD) » Definitions » FFO

CVKD (Cadrenal Therapeutics) FFO


View and export this data going back to 2023. Start your Free Trial

What is Cadrenal Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.


Cadrenal Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
822 A1A North, Suite 306, Ponte Vedra, FL, USA, 32082
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
Executives
John Raymond Murphy director 233 S PATTERSON AVE, SPRINGFIELD MO 65802
Quang X Pham director, 10 percent owner, officer: CEO and Chairman 89 MELROSE DRIVE, MISSION VIEJO CA 92692
Robert Lisicki director C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Douglas W Losordo officer: Chief Medical Officer 13 FOX MEADOW RD, SCARSDALE NY 10583
Steven Zelenkofske director 120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920
Matthew K Szot officer: Chief Financial Officer 802 NORTH DOUTY STREET, HANFORD CA 93230
Glynn Wilson director 2483 NE JULEP STREET, ISSAQUAH WA 98029